Eli Lilly and Company announced last friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending the approval of baricitinib for the treatment of adults with moderate to severely active rheumatoid arthritis (R
Osteoporosis is a major public health problems and is associated with a high burden of fractures and subsequent increased mortality.
Gastrointestinal perforation is a rare but serious complication that RA patients may be at particular risk for.
No new osteoporosis drugs hit the market this year, but two are progressing through the development pipeline and are showing promise.
Do hospitalized Medicare beneficiaries treated by female internists have lower rates of 30-day mortality and hospital readmission than those patients treated by men? A new study published online by JAMA Internal Medicine suggests that they do.
Dr. Jack Cush reviews highlights from this week on RheumNow.com
Combe and leading European rheumatologist have published an update to the 2007 European League Against Rheumatism (EULAR) recommendations for management of early arthritis.
Neuropsychiatric manifestations of systemic lupus erythematosus (SLE) may occur in up to half of patients in their lifetime.
However, dementia is often not reported or studied in cohorts with neurologic disease in lupus.
The U.S. Supreme Court has declined to hear a case over whether companies that make biosimilar drugs must wait six months after federal approval before they bring them to the market.
Researchers from Manchester, UK have reported the results of their BRAGGSS study showing that certolizumab (CZP) random drug levels and anti-drug antibody (ADAbs) levels can predict optimal outcomes in CZP treated rheumatoid arthritis patients.
Combustible and smokeless tobacco use causes adverse health outcomes, including cardiovascular disease and multiple types of cancer. Cigarette consumption in the United States has declined overall since the 1960s, but consumption of other tobacco products has not.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
